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a b s t r a c t
Background: Cytokines are key immune mediators in physiological and disease processes,
whose increased levels have been associated with the physiopathology of hematopoietic
malignancies, such as myeloproliferative neoplasms.
Methods: This study examined the plasma cytokine profiles of patients with essential throm-
bocythemia, primary myelofibrosis, polycythemia vera and of healthy subjects, and analyzed
correlations with JAK2 V617F status and clinical-hematological parameters.
Results: The proinflammatory cytokine levels were increased in myeloproliferative neo-
plasm patients, and the presence of the JAK2 V617F mutation was associated with high
IP-10 levels in primary myelofibrosis patients.
Conclusions: Essential thrombocythemia, primary myelofibrosis, and polycythemia vera
patients exhibited different patterns of cytokine production, as revealed by cytokine network
correlations. Together, these findings suggest that augmented cytokine levels are associated
with the physiopathology of myeloproliferative neoplasms.o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published© 2018 Associaçãby Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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protein 10 (IP-10), monocyte chemoattractant protein (MCP)-hematol transfus cell th
ntroduction
yeloproliferative neoplasms (MPN) are hematological dis-
rders characterized by increased proliferation and accu-
ulation of mature myeloid cells in the bone marrow and
eripheral blood. MPN are classified as Philadelphia (Ph)
hromosome-positive or -negative. The present investigation
ocusses on three Ph-negative MPN: essential thrombo-
ythemia (ET), primary myelofibrosis (PMF), and polycythemia
era (PV).1,2 These MPN are clonal disorders that result
rom malignant transformations of hematopoietic stem cells,
hich raise the number of mature myeloid blood cells, espe-
ially megakaryocytes/platelets in ET, erythrocytes in PV,
nd both megakaryocytes/platelets and granulocytes in PMF.
early 10–15% of ET, PMF, and PV patients progress to acute
yeloid leukemia.1,2
Constitutive activation of the Janus kinase 2 (JAK2)/signal
ransducer and activator of transcription (STAT) signaling
athway due to acquired somatic mutations in the JAK2, cal-
eticulin or MPL genes may drive the course of MPN. The
AK2 V617F mutation, which is detected in more than 90%
f PV patients and in about half of ET and PMF patients,
s located in the pseudokinase domain of the JAK2 protein
nd elicits a ‘pre-activation state’.3,4 This mutation seems
o confer the advantage of survival and proliferation to
yeloid hematopoietic cells independently of stimulatory sig-
als, leading to clonal expansion of myeloid progenitors and
ature cells.4 In MPN, the hematopoietic cells display an exac-
rbated response to cytokines and growth factors such as
rythropoietin, granulocyte-macrophage colony-stimulating
actor (GM-CSF), interleukin 3 (IL-3), and insulin-like growth
actor-1 (IGF-1).5 Autocrine stimulation may occur due to
ither defective cytokine receptors or constitutive activation
f the JAK2, STAT5, phosphoinositide 3-kinase (PI3K), signal-
egulated kinases extracellular (ERK), and protein kinase B
PKB) signaling pathways.5
MPN are considered onco-inflammatory disorders. The
oncept of ‘onco-inflammation’ proposes a crosstalk between
ancer cells and their inflammatory microenvironment sug-
esting that this plays a relevant role in the initiation and
rogression of cancers.6,7 MPN are characterized by abnormal
mmune system activity, increased monocyte/macrophage
ompartment, expansion of myeloid-derived suppressor cells,
bnormal frequency of regulatory T cells, and dysfunction of
atural killer and T CD4+ cells.8 In line with this concept,
hronic inflammation in MPN has been described as a poten-
ial facilitator for premature atherosclerosis development and
lonal evolution to acute myeloid leukemia.9 In addition,
brotic transformation, commonly found in PMF patients and
n myelofibrosis secondary to ET and PV, seems to be asso-
iated with an exacerbated inflammation status: cytokines
ecreted by bone marrow cells, in particular megakaryocytes,
robably activate endothelial cells and fibroblasts in the bone
arrow microenvironment, contributing to the establishment
f myelofibrosis.10
Elevated levels of cytokines have also been described in
ther hematological malignancies including chronic myeloid
eukemia (CML), non-Hodgkin lymphoma, multiple myeloma
nd myelodysplastic syndromes.11–16 Moreover, the high0 1 8;40(2):120–131 121
plasmatic levels of inflammatory cytokines are associ-
ated with the response of CML patients to tyrosine-kinase
inhibitors and with the prognosis of the aforementioned
hematological malignancies.11–16
Considering the critical role that cytokines play in different
hematological diseases and the contribution of inflammation
to cancer development, the present investigation examined
the differences between the cytokine profiles of ET, PMF and




The Ethics Committee for Human Research of the Faculdade
de Ciências Farmacêuticas de Ribeirão Preto (FCFRP-USP) and
Hospital das Clínicas, Faculdade de Medicina de Ribeirão Preto
(HC-FMRP-USP), Universidade de São Paulo, Ribeirão Preto,
SP, Brazil, approved the study protocol (number 348). All the
patients and healthy subjects signed informed written con-
sent forms in compliance with the guidelines established by
the Brazilian National Health Council (law 466/2012).
Blood samples
This study enrolled 11 ET patients, 16 PMF patients, and 20 PV
patients without any prior treatment, consulted at HC-FMRP-
USP and at Hospital Estadual de Transplantes Euryclides de
Jesus Zerbini (São Paulo, SP, Brazil) and 34 healthy subjects
(Control Group; CTRL) from the community of Ribeirão Preto.
Peripheral blood was collected from patients and healthy
subjects using EDTA tubes (Vacutainer
®
; Becton, Dickinson
and Company). The plasma samples were obtained after blood
centrifugation at 400 × g for 10 min at 4 ◦C (Eppendorf 5810R
Centrifuge), and stored at −80 ◦C until analysis. Patient’s sam-
ples were collected at diagnosis, without any previous therapy.
The MPN were classified using the World Health Organization
(WHO) 2016 classification.17
Analysis of hematological parameters
The Red blood cell count (RBC), white blood cell count
(WBC), platelet count, hemoglobin concentration (Hb), hema-
tocrit, mean corpuscular volume (MCV), mean corpuscular
hemoglobin (MCH), mean corpuscular hemoglobin concen-
tration (MCHC), and red cell distribution width (RDW) were
determined using the automatic ABX Micros 60 equipment
(HORIBA ABX SAS).
Measurement of cytokines and chemokines
A customized multiplex assay kit was used to determine the
plasma levels of: granulocyte-macrophage colony stimulat-
ing factor (GM-CSF), interferon (IFN)-2, IFN-, IFN -induced1, MIP-1, MIP-1, regulated on activation normal T cells
expressed and secreted (RANTES), tumor necrosis factor
(TNF)-, and the interleukins IL-1, IL-4, IL-5, IL-6, IL-10,
ther
(
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IL-12p70, and IL-17A (16-plex, EMD Millipore Corporation, MA,
USA). Fluorescence was recorded in a fluorescent bead-based
plate reader (Luminex1 MAGPIX1 System; Luminex Corpora-
tion, TX, USA). Data were analyzed using the Milliplex Analyst
software v3.5 (Millipore; VigeneTech Inc., Boston, MA, USA),
and a three-parameter logistic curve was fit.
Data analyses
Conventional statistical analyses were performed using
GraphPad Prism 5.0 software (Graph-Pad Software, San Diego,
CA, USA). Considering the nonparametric nature of all data
sets, the Mann–Whitney test was used to compare the exper-
imental groups, and the Spearman correlation test was used
to analyze the correlation between cytokine/chemokine levels
and the hematological parameters and clinical data. Statistical
differences were considered significant when p-values were
<0.05.
The correlations of cytokine/chemokine levels were com-
piled using the open source software Cytoscape (version 2.8;
http://www.cytoscape.org).16 The networks were constructed
using a circular layout, where the edges display the score of
the correlation index (r) as negative (r < 0), weak (r ≤ 0.35), mod-
erate (0.36 ≥ r ≤ 0.67) or strong (r ≥ 0.68).18
Additionally, the cytokine profile of each individual was
analyzed. First, all data from each cytokine/chemokine were
used to calculate the overall median value, which was used as
a cut-off point to classify each individual as a ‘high’ or ‘low’
producer of a given cytokine/chemokine. Next, the data were
organized in black-and-white scale diagrams to calculate the
frequency of high producers in each clinical group. Relevant
data (≥50%), previously characterized by Luiza-Silva et al.19
were highlighted in both bold and underline format. Radar
charts were built using Microsoft Excel (Microsoft Office 2013,
Las Vegas, USA) to characterize the overall frequency of indi-
viduals expressing high levels of each cytokine/chemokine in
each study group.
The analysis of overall cytokine profile was assessed to
characterize the general cytokine pattern of each group as
previously suggested by Vitelli-Avelar et al.20 but modified as
follows: the percentages of cytokine/chemokine production
were compiled using a four step platform, in this manner:
Table 1 – Hematological parameters and mutational status of p
patients.
CTRL ET
Age (years) – n (range) 57.2 (31–83) 54 (20–8
Gender – n (%)
Male 14 (42) 5 (55)
Female 20 (58) 4 (44)
JAK2 V617F carriers – n (%) – 5 (55)
Hemoglobin (g/dL) – n (range) – 13.01 (10.1
Platelets (× 103/L) – n (range) – 818 (399–
WBC (× 106/L) – n (range) – 9.02 (3.96
CTRL: control (healthy subjects); ET: essential thrombocythemia; PMF: pr
count.. 2 0 1 8;40(2):120–131
(i) Conventional statistical analysis;
(ii) Establishment of the overall median of cytokine/
chemokine production for each group;
iii) Classification of each group as low or high cytokine-
producer using the overall median values as the cut-off
point;
(iv) Creation of black-and-white scale diagrams for each
group.
These approaches have been shown as relevant to detect,
with high sensitivity, minor putative changes in the immuno-
logical profiles that are not detectable by conventional
statistical approaches.19,21,22
Results
Clinical and demographic characteristics of patients and
controls
The median ages were similar in the ET (54 years), CTRL (57.2
years), PV (66 years) and PMF (64 years) Groups. The gender
distribution in the CTRL Group was 42% male and 58% female,
in the ET Group it was 37% male and 63% female, in PMF it
was 75% male and 25% female and in the PV Group it was 55%
male and 45% female (Table 1). The JAK2 V617F mutation was
detected in 36%, 68%, and 100% of ET, PMF, and PV patients,
respectively (Table 1).
Essential thrombocythemia, primary myelofibrosis, and
polycythemia vera present elevated levels of inflammatory
cytokines/chemokines
The immune profiles of ET, PMF, and PV patients were ana-
lyzed by determining the plasma levels of 16 cytokines and
chemokines (Figure 1). Compared with the control group, the
three MPN patient groups exhibited elevated levels of GM-CSF,
IL-1, IL-4, IL-5, IL-6, IL-10, IFN-2, MIP-1, IL-12p70 and TNF-.
PMF patients also exhibited an increased level of IL-17A com-
pared to the CTRL Group, increased levels of IFN-, IL-12p70,
IL-17A and IP-10 compared to ET patients and increased lev-
els of IL-12p70, IL-4 and GM-CSF compared to PV patients. ET
patients exhibited an increased level of RANTES compared to
atients and demographic characteristics of controls and
PMF PV
1) 65 (44–80) 63 (39–83)
13 (76) 9 (39)
4 (23) 14 (60)
12 (70) 17 (74)
–17.1) 11.47 (5.88–17.4) 14.95 (9.9–21.5)
1293) 334 (38.5–1474) 425 (161–772)
–15.6) 11.71 (1.46–31.4) 10.21 (3.6–21.3)
imary myelofibrosis; PV: polycythemia vera; WBC: white blood cell
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Figure 1 – Cytokine and chemokine plasma levels in patients with myeloproliferative neoplasms and healthy subjects. The
plasma levels of GM-CSF, IFN-, IFN-, IL-1, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-17A, IP-10, MCP-1, MIP-1, MIP-1, RANTES,
and TNF- were measured in healthy subjects (CTRL; n = 34) and patients with essential thrombocythemia (ET; n = 11),
primary myelofibrosis (PMF; n = 16), and polycythemia vera (PV; n = 20). Statistical differences are represented in each graph
















he CTRL and PV Groups as well as an increased level of MIP-1
ompared to the CTRL Group. PV patients had a higher level
f MIP-1 compared to the CTRL Group. The MCP-1 level was
imilar among the four study groups (Figure 1).
AK2 V617F mutation status is associated with an
ncreased level of IP-10 in primary myelofibrosis
onsidering the pivotal role of the JAK2 V617F mutation
n the physiopathology of MPN,23 we evaluated the poten-
ial association of the JAK2 V617F mutation and the altered
ytokine/chemokine levels. Compared with PMF patients neg-
tive for the JAK2 V617F mutation, JAK2 V617F-positive PMF
atients exhibited an increased level of IP-10 (p = 0.0078;
igure 2). There was no association between the JAK2 V617F
utation status and the cytokine/chemokine levels in ET
atients.Alteration of the cytokine/chemokine biomarker network
in myeloproliferative neoplasm patients
To analyze the strength of correlation between the levels of the
studied cytokines/chemokines in the CTRL Group and in the
three MPN patient groups, we designed a network using Spear-
man’s correlation test (Figure 3). The network of the CTRL
Group presented strong connections between IL-12p70, IFN-
2, MIP-1, and MIP-1 and weak interactions between IL-4,
IL-6, IFN-2, IP-10, MIP-1, and MIP-1; and negative correla-
tions between IL-10, IFN- and RANTES (Figure 3A).
The ET patient network displayed many strong connections
involving GM-CSF, IL-4, IL-6, IL-10, IL-17A, IFN-2, IL-1, TNF-
, MIP-1, MIP-1, IP-10 and IFN-; (Figure 3B). In contrast to ET
and CTRL, the PMF patient network showed very few connec-
tions: strong interactions involving IFN-, IL-6, IL-17A, GM-CSF,
IL-6, IL-10, and IFN-2. The PMF patients also presented a
weak correlation between MIP-1 and IP-10 and a negative
124 hematol transfus cell ther
Figure 2 – The JAK2 V617F status influences cytokine
production in primary myelofibrosis (PMF) patients. The
IP-10 pro-inflammatory chemokine plasma level is
increased in JAK2 V617F-positive PMF patients (n = 5)
compared with JAK2 V617F-negative PMF patients (n = 11)
(p < 0.05; Mann–Whitney test).
this finding was more evident in PMF patients.correlation between GM-CSF and IP-10 (Figure 3C). The
PV patient network displayed strong interactions involving
Figure 3 – Systemic interactions between immunological biomar
neoplasms. The network analysis shows significant correlations
subjects (CTRL, Panel A) and in patients with primary myelofibro
essential thrombocythemia (ET; Panel D). The ‘r’ values obtained
determine the correlation strength: negative (r < 0), weak (r ≤ 0.35. 2 0 1 8;40(2):120–131
GM-CSF, IL-4, IL-6, IL-10, IL-12p70, IL-17A, IFN- and IFN-2
(Figure 3D).
Myeloproliferative neoplasm patients presented an
inflammatory status
To better understand and characterize the relationship
between the different MPN patient groups and their respec-
tive immune profiles, categorical analysis was performed
and the data compiled in black-and-white scale diagrams
(Figure 4A) . For this purpose, the overall median for
each cytokine/chemokine subset was calculated taking the
whole range of values obtained from the CTRL, PV, ET
and PMF Groups. The overall median percentage of each
cytokine/chemokine was used as the cut-off point to group
individuals into two categories, low and high producers. The
results indicate that the CTRL Group was composed of low
cytokine/chemokine producers, but the three MPN patient
groups exhibited the opposite profile: they presented high fre-
quencies of high producers of most cytokines/chemokines;Subsequently, radar charts were plotted to com-
pare the overall cytokine/chemokine profile of the high
cytokine/chemokine producers in the four study groups
kers is abnormal in patients with myeloproliferative
(p < 0.05) between cytokines and chemokines in healthy
sis (PMF; Panel B), polycythemia vera (PV; Panel C), and
after the Spearman’s correlation analysis were used to
), moderate (0.36 ≤ r ≤ 0.67), or strong (r ≥ 0.68).
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Figure 4 – Immune profile of healthy subjects (CTRL) and patients with primary myelofibrosis (PMF), polycythemia vera (PV),
and essential thrombocythemia (ET). (A) Plasma levels of GM-CSF, IFN-, IFN-, IL-1, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-17A,
IP-10, MCP-1, MIP-1, MIP-1, RANTES, and TNF- were used for categorical classification of CTRL, PMF, PV and ET groups
as high or low producers of a given cytokine/chemokine. Black and white blocks represent high and low producers of each
cytokine/chemokine, respectively. Each column represents a cytokine/chemokine, and each block represents each
individual’s cytokine/chemokine production pattern. The numbers below each column represent the frequency of high
producers of the cytokine/chemokine tested.
(B) Radar chart representation of the immune profile of healthy subjects (CTRL) and patients with essential
thrombocythemia (ET), primary myelofibrosis (PMF), and polycythemia vera (PV). Radar charts summarize the percentage of
high producers of each cytokine/chemokine in the study groups. The plasma levels of GM-CSF, IFN-, IFN-, IL-1, IL-4, IL-5,
IL-6, IL-10, IL-12p70, IL-17A, IP-10, MCP-1, MIP-1, MIP-1, RANTES, and TNF- were used for categorical classification of
s of athe CTRL, PMF, PV, and ET groups as high and low producer
(Figure 4B). We considered a cytokine/chemokine to be rel-
evant in the disease process when the frequency of high
producers was greater than 50%.19 In the CTRL Group, the
frequencies of high cytokine/chemokine producers for all the
cytokines/chemokines evaluated were less than 50%. The ET
patients presented high production frequencies for 12 of the
16 cytokines/chemokines analyzed. The PMF and PV patient
groups exhibited the highest frequencies among all the study
groups, showing high cytokine/chemokine productions for 16
and 14, respectively of the 16 cytokines/chemokines tested.
Inflammatory cytokine levels and hematological
parameters are correlated in myeloproliferative neoplasms
This study tested if the cytokine/chemokine levels correlate
to hematological parameters in MPN patients. In PMF patients
(Figure 5), GM-CSF and IL-12p70 levels correlated positively
with MCV; GM-CSF and IL-1 levels correlated positively with
MCH; and RANTES, IP-10 and IFN- levels correlated positively
with the platelet count. IP-10 levels correlated positively with
MCHC, IP-10, IL-17A, IL-5 and MIP-1 levels were negatively
correlated with RBC, while MIP-1 positively correlated with
Hb.
In PV patients (Figure 6), RDW correlated positively to IP-10
levels and negatively with IL-5 levels. IL-5 levels also correlated
negatively to RBC, WBC, Hb and MCHC. IL-4 levels correlated
negatively to Hb and hematocrit and MCHC positively corre-
lated to IFN- and MIP-1. In ET patients (Figure 7), IL-5 levels
correlated positively to MCV and MCH and TNF- correlated
positively to platelet counts.
Discussion
The hallmarks of immune deregulation and onco-
inflammation have been reported mostly in solid cancer
patients, but also identified in some MPN patients.24 Increased
levels of cytokines in PV and ET patients have indicated that
they play a critical role in the physiopathology of MPN and so
the measurement of their plasma levels might be useful for
the clinical and therapeutic stratification of patients.25 This
study assessed the different patterns of cytokine/chemokine
expression in patients with three types of MPN (ET, PMF,
and PV), their correlations with hematological parameters,given cytokine/chemokine.
associations with mutation status and interactions within
networks.
Elevated plasma levels of several cytokines and
chemokines were detected in ET, PMF and PV patients
compared to healthy subjects. This finding indicates that
an inflammatory process may be involved in the phys-
iopathology of MPN, as cytokines and chemokines act in
autocrine, paracrine and endocrine manners, and may even
affect the hematopoietic niche. The levels of two regula-
tory cytokines, IL-4 and IL-10, were increased in all patient
groups, which suggests an attempt to counterbalance the
excessive pro-inflammatory response. In addition, the levels
of cytokine/chemokine expression differed between the
three MPN groups. For instance, PMF patients exhibited
higher plasma levels of IFN-, IL-12p70 and IL-17A than ET
patients and higher plasma levels of TNF-, IL-4, IL12-p70
and GM-CSF than PV patients. ET patients exhibited higher
plasma levels of RANTES than CTRLs and PV, as well as higher
levels of MIP-1 than PV patients. IL-12 and IL-17 are pro-
inflammatory cytokines that participate in both innate and
adaptive immune responses and whose altered levels have
been correlated to the physiopathology of various diseases,
including cancer.26–28 RANTES, an important chemokine
associated with cancer progression and metastasis, acts as
a growth factor, stimulates angiogenesis and participates
in immune evasion mechanisms.29,30 In this context, the
increased levels of IL-12p70, IL-17A and RANTES in PMF
patients suggest that they bear a more intense inflammatory
process than ET or PV patients do.
The increased production of IP-10 in JAK2 V617F-positive
PMF patients indicates a pro-inflammatory profile, as this
cytokine, which is inducible by pro-inflammatory stimuli such
as IFN- and TNF-, presents pro-inflammatory properties.31
High levels of IP-10 seem to contribute to the pathogene-
sis of many organ-specific autoimmune diseases (such as
autoimmune thyroiditis, type 1 diabetes, Graves’ disease and
ophthalmopathy) and systemic autoimmune diseases (such
as rheumatoid arthritis, systemic sclerosis, psoriatic arthri-
tis, systemic lupus erythematosus and Sjögren syndrome),
besides being an important chemokine involved in the alloim-
mune response against kidney allografts.32,33The MPN driven JAK2 V617F mutation stimulates the JAK-
STAT3/5 pathway to boost inflammatory cytokine production
through autocrine and paracrine mechanisms.34 Positivity for
the JAK2 V671F mutation is associated with leukocyte and
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Figure 5 – Correlation between cytokine/chemokine plasma levels and hematological parameters in primary myelofibrosis
patients (n = 16). The figure depicts only the significant correlations (p < 0.05; non-parametric Spearman’s correlation).
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Figure 6 – Correlation between cytokine/chemokine plasma levels and hematological data in polycythemia vera patients
(n = 20). The figure depicts only the significant correlations (p < 0.05; non-parametric Spearman’s correlation).
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Figure 7 – Correlation between cytokine/chemokine plasma levels and hematological data in essential thrombocythemia










































2016/03265-3 and 2015/21237-4), the Conselho Nacional delatelet activation, and represents a thrombogenic factor in
PN.35,36 Little is known about the cytokine deregulation
ssociated with thromboembolic events in MPN and their
otential predictive values.10 Inflammation seems to be the
ajor contributor to the prothrombotic state in MPN, as well
s to bone marrow fibrosis, osteosclerosis, and angiogenesis.30
PN patients also exhibit a massive upregulation of IFN-
elated genes, particularly the IFN-inducible gene IFI27, and
evere deregulation of other inflammation and immune genes,
s demonstrated by the whole-blood transcriptional profiling
f several immune cells (granulocytes, monocytes, B cells, T
ells, and platelets).37
Ho et al., using human cytokine array membranes com-
ined to individual assets of enzyme-linked immunosorbent
ssay, enhanced chemiluminescence and high-throughput
f microspot, evaluated plasmatic levels of 79 cytokines in
ontrols and naïve PMF patients and described higher tis-
ue inhibitor levels related to tissue inhibitor of matrix
etalloproteinase-1 (TIMP-1), macrophage inflammatory
rotein-1 (MIP-1), and insulin-like growth factor binding
actor-2 (IGFBP-2).38 Differently from the current work they did
ot investigate these 79 cytokine plasmatic levels in PV and ET
atients.39
Vaidya et al. showed by multivariable analysis and multi-
lex bead-based assaying that the elevated plasmatic levels of
3 cytokines (IL-1, IL-4, EGF, IL-5, IL-7, IL-10, IL-17, TNF-, IFN-
, GM-CSF, MIP-1, MIP-1 and MCP-1) was associated with low
verall survival in a group of 65 PV and 127 PMF patients. More-
ver, similar to the current study, they showed that PMF and PV
atients present different patterns of cytokine production.39
In the same context, Tefferi et al., using a multiplex bio-
etric sandwich immunoassay and multivariable analysis
eported increased levels of IL-1, IL-1RA, IL-2R, IL-6, IL-8, IL-
0, IL-12, IL-13, IL-15, TNF-, G-CSF, IFN-, MIP-1, MIP-1, HGF,
FN-–IP-10, monokines induced by IFN- (MIG), MCP-1 and
ascular endothelial growth factor (VEGF) and decreased lev-
ls of IFN- in PMF patients compared to controls. The cytokine
evels were associated with shorter survival in PMF patients.40
These authors studied a higher number of patients than the
resent study; however, they did not associate the patients’
utation status and hematological parameters with the
ytokine profile and did not compare the cytokine levels
etween the different MPN patient groups. The present study
valuated, 16 plasmatic cytokines/chemokines in ET, PMF, and
V patients at diagnosis using a multiplex bead-based assayto identify a disease signature/network and to associate it
to the mutation status and hematological parameters. This
study found that the studied MPN patients presented dysfunc-
tional cytokine/chemokine production patterns characterized
by high frequencies of ‘high’ cytokine/chemokine producers
compared to healthy subjects. Furthermore, the correlation
between the cytokine/chemokine levels and hematological
parameters indicates that immune dysregulation may affect
the production of hematological cells and favor their exacer-
bated proliferation.
Taken altogether, the data reported herein demonstrated
that (i) the plasma cytokine/chemokine profile of ET, PMF,
and PV patients are altered, which is most evident in
PMF patients; and (ii) the JAK2 V617F status influences
the cytokine/chemokine profile in PV patients. Our findings
emphasize the overproduction of cytokines and chemokines
in MPN patients, culminating in a pro-inflammatory state.
The increased levels of pro-inflammatory cytokines are
associated with worse prognosis and shorter survival in MPN
patients. Therapies targeting the pro-inflammatory cytokine
profile seem to improve the quality of life and life expectancy
of MPN patients. In this context, the JAK2 inhibitor ruxolu-
tinib acts by decreasing the production of pro-inflammatory
cytokines (inhibiting the cytokine gene transcription), thereby
reducing the constitutional symptoms and splenomegaly
(35%) in PMF patients.41,42 However, the JAK2 inhibitor poten-
tial against cytokine production in this therapy is not curative
and does not impair MPN progression to leukemia. Thus, we
must continue to study the molecular mechanisms involved
in MPN pathogenesis to search for new efficient therapies for
these disorders.
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